Scholarlink

Context <p>Oral squamous cell carcinoma (OSCC) is a malignant epithelial neoplasm that affects the head and neck region and contributes to around 84–97% of oral cancer. Aurora kinase A is a key regulator of cell cycle progression and mitotic spindle assembly, which plays a critical role in the development and progression of OSCC. Knockdown of AURKA suppresses cell proliferation, migration, and invasion, while inducing apoptosis and reactive oxygen species generation in oral squamous cell carcinoma. This highlights the functional significance of AURKA in tumor progression and supports its potential as a novel therapeutic target. This study focuses on the in silico evaluation of anticancer peptides (ACPs) as potential inhibitors of AURKA, aiming to identify novel peptide-based drugs for targeting oral cancer.</p> Methods <p>Using advanced computational techniques, including molecular docking, molecular dynamics simulation, and pharmacokinetics profiling, we have screened 116 ACPs to evaluate their binding affinity, structural stability, and effect of mutagenesis. Interestingly, it was observed that AIP19 peptide demonstrated high binding affinity of -1049.8 and exhibited strong binding affinity to the catalytic pocket of AURKA, forming key hydrophobic interactions with residues such as Leu139, Phe144, Val147, Leu210, and Trp277, along with hydrogen bonds involving Lys143, Pro214, and Glu260. These interactions highlight its potential as a promising peptide-based inhibitor. Using the in silico mutagenesis approach, several peptide variants of AIP19 were generated to study the impact of specific mutations on the binding affinity. The results indicated that AIP19 mutations, including F5W, V6Y, V9W and M11Y could potentially enhance the peptide’s binding affinity for AURKA. Furthermore, the drug likeness properties, low toxicity, and better biocompatibility of peptides highlight their potential as cancer-targeted therapeutics with minimal adverse effect. The stability and binding affinity of the AURKA-peptide complexes were evaluated using molecular dynamic simulation and MM GB/PBSA analysis. This study highlights the effectiveness of in silico methodologies in accelerating the discovery and optimization of peptide-based drugs. The identified ACPs represent a promising step toward the development of safe and effective therapeutics against OSCC, offering a novel approach to combat tumor progression that leverages structure-based peptide engineering to enhance binding affinity. This study lays the groundwork for future experimental validation of AIP19, highlighting its promise as a targeted therapeutic strategy for OSCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In silico evaluation of anticancer peptide as a novel therapeutic agent against AURKA for targeting oral carcinogenesis

  • 期刊论文

  • 发表日期：

    2025年12月6日

查看全文
  • Deepak Saravanan,
  • Monisha Mohan

摘要

Context

Oral squamous cell carcinoma (OSCC) is a malignant epithelial neoplasm that affects the head and neck region and contributes to around 84–97% of oral cancer. Aurora kinase A is a key regulator of cell cycle progression and mitotic spindle assembly, which plays a critical role in the development and progression of OSCC. Knockdown of AURKA suppresses cell proliferation, migration, and invasion, while inducing apoptosis and reactive oxygen species generation in oral squamous cell carcinoma. This highlights the functional significance of AURKA in tumor progression and supports its potential as a novel therapeutic target. This study focuses on the in silico evaluation of anticancer peptides (ACPs) as potential inhibitors of AURKA, aiming to identify novel peptide-based drugs for targeting oral cancer.

Methods

Using advanced computational techniques, including molecular docking, molecular dynamics simulation, and pharmacokinetics profiling, we have screened 116 ACPs to evaluate their binding affinity, structural stability, and effect of mutagenesis. Interestingly, it was observed that AIP19 peptide demonstrated high binding affinity of -1049.8 and exhibited strong binding affinity to the catalytic pocket of AURKA, forming key hydrophobic interactions with residues such as Leu139, Phe144, Val147, Leu210, and Trp277, along with hydrogen bonds involving Lys143, Pro214, and Glu260. These interactions highlight its potential as a promising peptide-based inhibitor. Using the in silico mutagenesis approach, several peptide variants of AIP19 were generated to study the impact of specific mutations on the binding affinity. The results indicated that AIP19 mutations, including F5W, V6Y, V9W and M11Y could potentially enhance the peptide’s binding affinity for AURKA. Furthermore, the drug likeness properties, low toxicity, and better biocompatibility of peptides highlight their potential as cancer-targeted therapeutics with minimal adverse effect. The stability and binding affinity of the AURKA-peptide complexes were evaluated using molecular dynamic simulation and MM GB/PBSA analysis. This study highlights the effectiveness of in silico methodologies in accelerating the discovery and optimization of peptide-based drugs. The identified ACPs represent a promising step toward the development of safe and effective therapeutics against OSCC, offering a novel approach to combat tumor progression that leverages structure-based peptide engineering to enhance binding affinity. This study lays the groundwork for future experimental validation of AIP19, highlighting its promise as a targeted therapeutic strategy for OSCC.